Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Judith Boer

Senior Postdoc, supervision oncogenomics research line.
Judith Boer
Judith Boer
Personalized treatment for pediatric leukemia patients

Dr. Judith M. Boer obtained her MSc degree in Biomedical Sciences at Leiden University in 1991 and her PhD degree in cell biology and genetics at Erasmus University Rotterdam in 1997. Part of her PhD research on the role of oncogenic fusion proteins in acute myeloid leukemia was performed at St. Jude Children’s Research Hospital in Memphis, US. As a postdoc, Judith pioneered array technology and omics data analysis at the German Cancer Research Center (DKFZ) and continued this line of research as an assistant professor at Leiden University Medical Center. She joined the Den Boer research group in 2010 and moved to the Princess Máxima Center for pediatric oncology in Utrecht in 2018, where she is now a permanent staff member co-supervising PhD students on oncogenomics and precision medicine projects. Bridging from lab to clinic, she is involved in the development of genetic stratification for first-line therapy and identification of targets for precision medicines in individual patients to improve the outcome of pediatric leukemia patients.
  • Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia

    • jun. 2022
    • Edoardo, Pennesi, et al
    • Leukemia
  • MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia

    • nov. 2021
    • Elena, Boldrin, et al
    • Blood
  • Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study

    • okt. 2021
    • Judith M, Boer, et al
    • Leukemia
  • Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia

    • okt. 2021
    • Naomi, Michels, et al
    • The Lancet. Haematology
  • Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all

    • sep. 2021
    • Roland P, Kuiper, et al
    • British journal of haematology
View all publications